Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell...

Area of Science:

• Hematology
• Cell Biology
• Pediatric Oncology

Background:

• Mesenchymal stem cell (MSC) dysfunction contributes to myelodysplastic syndromes (MDS) pathophysiology.
• Pediatric MDS exhibits distinct biological and clinical features compared to adult MDS.
• Understanding MSCs in pediatric MDS is crucial due to potentially different underlying mechanisms.

Purpose of the Study:

• To investigate the proliferation capacity of MSCs derived from pediatric MDS patients at the clonal cell level.
• To compare the proliferation of MSCs from pediatric MDS patients with healthy controls.

Main Methods:

• Isolation and identification of bone marrow MSCs from pediatric MDS patients and healthy controls.
• Assessment of MSC proliferation capacity, cell cycle progression (via PI staining and flow cytometry), and cellular senescence (via β-galactosidase staining and telomere length).

Main Results:

• Pediatric MDS-derived MSCs exhibited normal differentiation potential and surface marker expression, similar to healthy controls.
• MSCs from pediatric MDS patients demonstrated defective proliferation compared to healthy controls.
• Pediatric MDS-derived MSCs showed increased susceptibility to cellular senescence and a reduction in the S phase of the cell cycle.

Conclusions:

• Pediatric MDS-derived MSCs retain fundamental characteristics of normal MSCs.
• Defective proliferation in pediatric MDS-derived MSCs is a key finding.
• Cellular senescence is a potential contributing factor to the impaired proliferation observed in pediatric MDS-derived MSCs.